The drug has no generic equivalent and is the only polysulfated glycosaminoglycan approved by the U.S. Food and Drug Administration, Luitpold added. The plant renovations, intended to guarantee higher quality standards, depleted the supply of Adequan, the company stated. "We have carefully managed supply to allocate inventory optimally, but the product will be out of stock for a short period of time,” Luitpold acknowledged. "We expect to resume shipments of the 5mL in early July, followed by the 50mL in August.” Approved for equine use in 1984, no other polysulfated glycosaminoglycan has been developed to treat noninfectious degenerative or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses, the company stated. "We recommend careful evaluation of any alternative product claims to ensure safety and efficacy,” Luitpold added. The company is fielding questions through its Customer Service Department at 800-458-0163. Updates and more information will be posted at Adequan.com. An Adequan i.m. shortage also occurred in 2011, when back orders were in effect because of issues involving human drugs manufactured at the plant. <HOME>
